| 货号 | CAS号 |
|---|---|
| R127750-10mg | 625115-55-1 |
| R127750-500mg | 625115-55-1 |
| R127750-50mg | 625115-55-1 |
| R127750-5mg | 625115-55-1 |
| R127750-100mg | 625115-55-1 |
| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 应用 | Riociguat (BAY 63-2521)是可溶的鸟苷酸环化酶刺激剂。 |
| 生化机理 | Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. Riociguat (BAY 63-2521; BAY 632521) is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators. |
| 别名 | 利奥西呱;N-[4,6-二氨基-2-[1-[(2-氟苯基)甲基]-1H-吡唑并[3,4-B]吡啶-3-基]-5-嘧啶基]-N-甲基氨基甲酸甲酯;BAY 63-2521; BAY 632521;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester |
